Sumatriptan
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Sumatriptan: From Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Sumatriptan is a 5-HT1B/1D receptor agonist with an established role in the acute treatment of migraine. The TxGNN model predicts a strong association with Migraine with Brainstem Aura, but this signal is currently supported only by mechanistic and observational literature (18 publications, 0 clinical trials) — and this migraine subtype is conventionally regarded as a relative/absolute contraindication for triptans, so the finding requires careful safety review before any further action.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine (acute treatment) — based on established pharmacology; no Danish licence data is available for this drug |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L4 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, sumatriptan is a selective 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits vasoactive neuropeptide release from perivascular trigeminal axons, a mechanism well established for treating acute migraine.
Migraine with brainstem aura (formerly “basilar-type migraine”) is a subtype within the broader migraine spectrum, which is why TxGNN’s knowledge-graph model links it strongly to sumatriptan — the drug’s original indication and this predicted indication share the same disease family and receptor biology.
However, this mechanistic similarity cuts both ways: because sumatriptan’s vasoconstrictive action could theoretically affect brainstem circulation, most clinical guidelines list migraine with brainstem aura as a relative or absolute contraindication for triptans rather than an approved use. The high TxGNN score reflects general “sumatriptan–migraine” relatedness in the knowledge graph, not a validated safety profile for this specific aura subtype — the mechanistic and safety signals point in opposite directions, which is why this candidate requires a safety-first review rather than a straightforward efficacy assessment.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23657930 | 2014 | RCT | Phytotherapy Research | Double-blind RCT comparing ginger powder to sumatriptan for acute migraine ablation |
| 25600718 | 2015 | Guideline/Evidence Assessment | Headache | American Headache Society evidence review of acute migraine pharmacotherapies, including triptans |
| 25841032 | 2015 | Cohort/Comparative | Neurology | Sumatriptan shows reduced efficacy in migraine with aura vs. without aura — directly relevant caution for this subtype |
| 1313746 | 1992 | RCT | Cephalalgia | Double-blind, placebo-controlled trial of oral sumatriptan 200mg in acute migraine with aura |
| 33567890 | 2021 | RCT | Cephalalgia | Randomised trial: early sumatriptan treatment prevents PACAP38-induced migraine attacks |
| 31135819 | 2019 | Mechanistic/Imaging Study | JAMA Neurology | PET imaging study of central 5-HT1B receptor binding during sumatriptan treatment |
| 38307660 | 2024 | Review | Handbook of Clinical Neurology | Overview of status migrainosus, a recognized complication across migraine (with/without aura) |
| 8536293 | 1995 | Review | Cephalalgia | Critical review of clinical experience with sumatriptan in migraine and cluster headache management |
| 27910087 | 2017 | Review | Headache | Review of menstrual migraine treatment options |
| 37123778 | 2023 | Review | Cureus | Review of migraine management approaches in pregnancy and breastfeeding |
Denmark Market Information
Sumatriptan currently has no marketing authorisation on record with the Laegemiddelstyrelsen (Danish Medicines Agency) in the dataset used for this analysis (0 licences); market status is recorded as Not marketed.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Important note: although formal warning/contraindication data was not retrievable for this analysis, published literature (e.g., PMID 25841032) and general triptan-class labelling conventionally treat migraine with brainstem aura as a contraindicated or high-caution use for triptans due to theoretical cerebrovascular vasoconstriction risk. This should be explicitly verified against the SmPC before any clinical consideration.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score reflects general sumatriptan–migraine relatedness rather than validated evidence for this specific aura subtype. No clinical trials support this indication, evidence level is L4 (mechanistic/literature only), and the predicted indication conflicts with the conventional contraindication profile of triptans in brainstem-type migraine — safety concerns must be resolved before this can advance.
To proceed, the following is needed:
- SmPC warnings/contraindications for sumatriptan (Blocking data gap — required before any S1 safety screening)
- Verified mechanism of action data to support or refute the mechanistic rationale
- A dedicated safety/contraindication review specifically addressing brainstem aura and triptan vasoconstriction risk
- If pursued, a marketing authorisation pathway with the Laegemiddelstyrelsen, as none currently exists
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.